Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
暂无分享,去创建一个
N. Halama | D. Jäger | M. Kieser | O. Sedlaczek | M. Gaida | B. Leuchs | J. Rommelaere | C. E. Engeland | G. Ungerechts | C. Springfeld | V. Daniel | M. Dahm | A. Angelova | Maximilian Pilz | N. Hohmann | O. Krebs | B. Huber | Jacek Hajda | Veronika Frehtman | A. Mavratzas | J. Schreiber | M. Mertens | Christine E. Engeland
[1] C. la Vecchia,et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] M. O'Hara,et al. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. , 2020, Cancer cell.
[3] H. Kaufman,et al. Integrating oncolytic viruses in combination cancer immunotherapy , 2018, Nature Reviews Immunology.
[4] B. Nelson,et al. Oncolytic viruses as engineering platforms for combination immunotherapy , 2018, Nature Reviews Cancer.
[5] B. Nelson,et al. Publisher Correction: Oncolytic viruses as engineering platforms for combination immunotherapy , 2018, Nature Reviews Cancer.
[6] Michael E. Lassman,et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.
[7] N. Halama,et al. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol , 2017, BMC Cancer.
[8] A. Unterberg,et al. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] Benjamin L. Musher,et al. Oncolytic viral therapy for pancreatic cancer , 2017, Journal of surgical oncology.
[10] B. Leuchs,et al. Standardized large-scale H-1PV production process with efficient quality and quantity monitoring. , 2016, Journal of virological methods.
[11] J. Rommelaere,et al. Double-faceted mechanism of parvoviral oncosuppression. , 2015, Current opinion in virology.
[12] Troy Guthrie,et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Rommelaere,et al. Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients , 2015, Front. Bioeng. Biotechnol..
[14] Bernard Rachet,et al. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study , 2015, The Lancet.
[15] P. Tattersall,et al. Parvoviruses: Small Does Not Mean Simple. , 2014, Annual review of virology.
[16] F Levi,et al. European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[18] J. Ferlay,et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.
[19] A. Marchini,et al. Molecular Pathways: Rodent Parvoviruses—Mechanisms of Oncolysis and Prospects for Clinical Cancer Treatment , 2012, Clinical Cancer Research.
[20] M. von Knebel Doeberitz,et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol , 2012, BMC Cancer.
[21] J. Rommelaere,et al. Oncolytic parvoviruses as cancer therapeutics. , 2010, Cytokine & growth factor reviews.
[22] N. Giese,et al. Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV , 2009, Clinical Cancer Research.
[23] A. Venook,et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial , 2001, Gene Therapy.
[24] F. Motoi,et al. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. , 2000, Human gene therapy.
[25] S. Nomoto,et al. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer , 1999, Journal of surgical oncology.
[26] E. Slater. Chemotherapy in pancreatic cancer. , 1981, British medical journal.
[27] J. Sever,et al. Attempts to isolate H-1 virus from spontaneous human abortions: a negative report. , 1970, Teratology.
[28] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[29] J. Stamp,et al. Viral diseases , 1975, Nature.